Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Nektar Therapeutics - Common Stock
(NQ:
NKTR
)
25.41
-0.31 (-1.22%)
Streaming Delayed Price
Updated: 11:41 AM EDT, Aug 14, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Nektar Therapeutics - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
12 Health Care Stocks Moving In Thursday's After-Market Session
April 14, 2022
Gainers
Via
Benzinga
Best Performers Since 3/14 Pivot
March 22, 2022
Early last week, the US equity market pivoted, gaining 1%+ for four consecutive days between last Tuesday and last Friday. Sentiment has shifted amongst the investing community for the time being.
Via
Talk Markets
The Week Ahead In Biotech (March 20-26): Focus On Zogenix FDA Decision, Dermatology Conference Presentations & Earnings
March 20, 2022
Biotech stocks rebounded along with the broader market in the week ending March 18, as risk appetite returned. Multiple conference presentations, clinical readouts and earnings news dictated sentiment...
Via
Benzinga
Why is Nektar Therapeutics (NKTR) Stock Down Today?
March 14, 2022
Nektar Therapeutics is down big today after ending some of its clinical trials. What's going on with NKTR stock?
Via
InvestorPlace
Earnings Scheduled For February 28, 2022
February 28, 2022
Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (...
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
February 04, 2022
On Friday, 209 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Meta Platforms (NASDAQ:FB) was the largest firm on a market cap...
Via
Benzinga
What 4 Analyst Ratings Have To Say About Nektar Therapeutics
March 15, 2022
Analysts have provided the following ratings for Nektar Therapeutics (NASDAQ:NKTR) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish...
Via
Benzinga
Where Nektar Therapeutics Stands With Analysts
March 15, 2022
Nektar Therapeutics (NASDAQ:NKTR) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 15, 2022
March 15, 2022
Upgrades For Turquoise Hill Resources Ltd (NYSE:TRQ), BMO Capital upgraded the previous rating of Underperform to Market Perform. Turquoise Hill Resources earned $0.78 in the...
Via
Benzinga
10 Biggest Price Target Changes For Tuesday
March 15, 2022
Wells Fargo cut the price target on Coupa Software Incorporated (NYSE: LPI) from $190 to $80. Laredo Petroleum shares fell 29.8% to $63.10 in pre-market trading.
Via
Benzinga
96 Biggest Movers From Yesterday
March 15, 2022
Gainers Volt Information Sciences, Inc. (NYSE: VOLT) shares surged 94.7% to close at $5.88 on Monday after the company announced it would be acquired for $6 per share. Incannex...
Via
Benzinga
Mid-Afternoon Market Update: Dow Turns Negative; Turquoise Hill Resources Shares Spike Higher
March 14, 2022
U.S. stocks turned lower toward the end of trading on Monday as the Dow Jones dropped 100 points, after surging more than 400 points earlier during the session. The Dow...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
March 14, 2022
Gainers Incannex Healthcare (NASDAQ:IXHL) stock moved upwards by 48.0% to $20.95 during Monday's regular session. The company's market cap stands at $1.0 billion....
Via
Benzinga
Knightscope News: Why Is KSCP Stock Up Today?
March 14, 2022
Knightscope (KSCP) stock is on the move Monday following news that the company signed onto a new real estate development project.
Via
InvestorPlace
Mid-Day Market Update: Markets Mixed; Nasdaq Drops Over 100 Points
March 14, 2022
The Nasdaq index turned lower midway through trading, losing more than 100 points on Monday. The Dow traded up 0.61% to 33,143.88 while the NASDAQ fell 1.13% to 12,698.26....
Via
Benzinga
50 Stocks Moving In Monday's Mid-Day Session
March 14, 2022
Gainers Volt Information Sciences, Inc. (NYSE: VOLT) shares jumped 95.2% to $5.89 after the company announced it would be acquired for $6 per share. AgriFORCE Growing Systems,...
Via
Benzinga
Bristol Myers, Nektar Melanoma Doublet Therapy Trial Fails To Show Clinical Benefit
March 14, 2022
Bristol Myers Squibb Co (NYSE: BMY) and Nektar Therapeutics (NASDAQ: NKTR) have an update following the first analysis of the Phase 3 PIVOT IO-001 study of...
Via
Benzinga
Mid-Morning Market Update: Markets Open Higher; Crude Oil Dips 8%
March 14, 2022
U.S. stocks opened on a strong note this morning, with the Dow Jones gaining 300 points on Monday. Following the market opening Monday, the Dow traded up 0.99% to 33,269.95 while...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 14, 2022
March 14, 2022
Upgrades Janney Montgomery Scott upgraded the previous rating for Enova International Inc (NYSE:ENVA) from Neutral to Buy. Enova International earned $1.61 in the fourth quarter,...
Via
Benzinga
Nektar Therapeutics Loses Half Its Value As Bristol Myers-Paired Melanoma Test Flops
March 14, 2022
Sentiment was low heading into the study and analysts aren't hopeful for other tests.
Via
Investor's Business Daily
Why Nektar Therapeutics Shares Are Falling Today
March 14, 2022
Nektar Therapeutics (NASDAQ: NKTR) is trading significantly lower Monday morning after the company's Phase 3 PIVOT trial, in combination with Bristol-Myers Squibb Co (...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
March 14, 2022
Gainers Erytech Pharma (NASDAQ:ERYP) stock rose 18.7% to $1.65 during Monday's pre-market session. The market value of their outstanding shares is at $51.1 million....
Via
Benzinga
Bristol Myers Squibb and Nektar Announce Update on Phase 3 PIVOT IO-001 Trial Evaluating Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab) in Previously Untreated Unresectable or Metastatic Melanoma
March 14, 2022
From
Bristol Myers Squibb
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For March 9, 2022
March 09, 2022
Upgrades Roth Capital upgraded the previous rating for Hudson Technologies Inc (NASDAQ:HDSN) from Neutral to Buy. For the fourth quarter, Hudson Technologies had an EPS of $0.13,...
Via
Benzinga
Nektar Therapeutics: Q4 Earnings Insights
February 28, 2022
Nektar Therapeutics (NASDAQ:NKTR) reported its Q4 earnings results on Monday, February 28, 2022 at 04:00 PM. Here's what investors need to know about the announcement....
Via
Benzinga
Earnings Outlook For Nektar Therapeutics
February 25, 2022
Nektar Therapeutics (NASDAQ:NKTR) is set to give its latest quarterly earnings report on Monday, 2022-02-28. Here's what investors need to know before the announcement. Analysts...
Via
Benzinga
Big Trend Occurring in Triple-Negative Breast Cancer Treatment Is The Shift Towards Combination Therapy
December 10, 2021
Palm Beach, FL – December 10, 2021 – FinancialNewsMedia.com News Commentary – Ongoing advancements in cancer research continue to lead to the introduction of newer and better treatment options...
Via
FinancialNewsMedia
7 Drug Stocks to Buy Now While They’re Still on Sale
November 30, 2021
Covid-19 stocks soared to unsustainable highs as investors ignored drug stocks with a deep pipeline of products for the decade ahead.
Via
InvestorPlace
Topics
Supply Chain
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
December 06, 2021
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative...
Via
Benzinga
The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance
November 10, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus MorphoSys COO To Leave To Pursue Other Opportunities MorphoSys AG (NASDAQ:...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.